Recursion predicts protein targets for 36B compounds; Q2 net loss $76.7M, revenue $11M

RECURSION PHARMACEUTICALS, INC.

Predicted protein targets for ~36B compounds in Enamine REAL Space, evaluating 2.8 quadrillion target-compound pairs using NVIDIA DGX Cloud.
Q2 2023 revenue $11.0M (up from $7.7M); net loss $76.7M (up from $65.6M); cash $405.9M, excluding $50M NVIDIA investment.
Received $50M investment from NVIDIA; collaboration to build AI foundation models for drug discovery.
Appointed David Mauro as CMO and Nathan Hatfield as Chief Legal Officer.
First Phase 1 data readout for REC-3964 expected in Q3 2023; multiple pipeline catalysts through 2024-2025.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

RECURSION PHARMACEUTICALS, INC. reported financial results for second quarter ending June 30, 2023.

Period: second quarter ending June 30, 2023
Result: reported results

Exact text from the filing

Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates and financial results for its second quarter ending June 30, 2023.

View on SEC.gov

16 earnings releases filed in the last 30 days. Browse all earnings releases →

RECURSION PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001601830-23-000056

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.